A significant increase in the monoamine oxidase MAO-A is found in association with the pathogenesis of major depressive disorders [95], and selective serotonin reuptake inhibitor treatment elevated MAO-A binding in the brain regions of patients with depression, which contributes to recurrence [96]. Here, MAOA is linked to depressive symptom measurement.